Collegium Pharmaceutical, Inc
A pharmaceutical company making medicines for pain and ADHD, including the opioid painkiller Xtampza ER (built on its DETERx abuse-deterrent technology), Belbuca, the Nucynta products, and Jornay PM, an evening-dosed ADHD stimulant. Founded in 2002 by Michael Heffernan to develop safer opioids, its name comes from the Latin "collegium," meaning a band of colleagues working together. The company even named its technology DETERx — a nod to deterring misuse, which is why its microsphere-in-capsule pain pills are hard to crush or inject.
Sold 25.0K
Granted 371.9K · Sold 73.1K
Granted 49.9K · Sold 22.4K
Granted 217.8K
Granted 209.3K · Sold 72.2K
Granted 49.9K · Sold 5.4K
Granted 239.7K · Sold 184.4K
Granted 52.3K · Sold 34.9K
Granted 111.5K · Sold 28.1K
Granted 99.6K · Sold 20.2K
Granted 302.3K · Sold 274.5K
Granted 63.9K · Sold 37.7K
Granted 26.2K · Sold 3.6K
Granted 7.7K
Granted 12.5K
Granted 7.7K
Granted 28.3K
Granted 31.3K · Sold 4.5K
Granted 17.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Rosen David Efraim +1 co-filer10% owner · 1 transaction | — | 6.29Mas of Aug 2025 | — | — | 25.0K |
| Ciaffoni JosephPresident and CEO, Director · 12 transactions | +91.4% | 526.3Kas of Feb 2024 | 371.9K | — | 73.1K |
| Freund John GordonDirector · 9 transactions | — | 195.0K | 49.9K | — | 22.4K |
| Karnani VikramPresident and CEO, Director · 5 transactions | — | 176.6K | 217.8K | — | — |
| Tupper ColleenEVP & Chief Financial Officer · 21 transactions | +39.7% | 147.3K | 209.3K | — | 72.2K |
| Santini GinoDirector · 6 transactions | +65.5% | 112.5K | 49.9K | — | 5.4K |
| Kuhlmann Shirley R.EVP and General Counsel · 22 transactions | -9.5% | 108.1Kas of Mar 2025 | 239.7K | — | 184.4K |
| Fallon John A.Director · 5 transactions | +111% | 99.5K | 52.3K | — | 34.9K |
| Smith Thomas BEVP and Chief Medical Officer · 15 transactions | +173.6% | 85.3K | 111.5K | — | 28.1K |
| Dieter DavidEVP & General Counsel · 7 transactions | — | 77.1K | 99.6K | — | 20.2K |
| Dreyer ScottEVP & Chief Commercial Officer · 34 transactions | -44.2% | 75.3K | 302.3K | — | 274.5K |
| Bohlin Garen GDirector · 7 transactions | +58.6% | 71.0K | 63.9K | — | 37.7K |
| Balice-Gordon Rita J.Director · 4 transactions | +58.2% | 61.4K | 26.2K | — | 3.6K |
| Melincoff Gwen ADirector · 1 transaction | +17.2% | 52.5Kas of May 2024 | 7.7K | — | — |
| Heffernan Michael ThomasDirector · 2 transactions | +33.1% | 50.3Kas of Feb 2025 | 12.5K | — | — |
| McFarlane Neil F.Director · 1 transaction | +18.5% | 49.4Kas of May 2024 | 7.7K | — | — |
| Paya Carlos VDirector · 2 transactions | — | 28.3K | 28.3K | — | — |
| Lurker NancyDirector · 4 transactions | — | 26.8K | 31.3K | — | 4.5K |
| Glancy Donovan MichaelDirector · 1 transaction | — | 17.5K | 17.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -786.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.